Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
11°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cybin Inc
(NY:
CYBN
)
10.64
+0.82 (+8.35%)
Official Closing Price
Updated: 8:00 PM EST, Nov 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cybin Inc
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
38
39
Next >
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Initiates Dosing of First Participants in Phase 1 Clinical Trial
May 24, 2023
Via
Investor Brand Network
Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial
May 24, 2023
From
Cybin Inc.
Via
Business Wire
Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More
May 15, 2023
Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths...
Via
Benzinga
Trial On DMT Drug For Anxiety And Depression Ends Participant Dosing, Study Results Soon Released
May 09, 2023
Clinical-stage biopharma company Cybin Inc. (NYSE: CYBN) has completed participant dosing on the part 2 of 3 of its Phase 1 trial assessing intravenous (IV) administration of proprietary DMT drug...
Via
Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Doses Last Subject in Phase 1, Part B CYB004-E Trial
May 09, 2023
Via
Investor Brand Network
Cybin Announces Last Subject Dosed in Part B of its Phase 1 CYB004-E Trial
May 09, 2023
From
Cybin Inc.
Via
Business Wire
April Psychedelic Drug Stocks Recap: The Ups And Downs
April 30, 2023
Via
Talk Markets
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO to Participate at Upcoming Milken Institute Global Conference
April 28, 2023
Via
Investor Brand Network
Cybin to Participate at the 26th Annual Milken Institute Global Conference
April 28, 2023
From
Cybin Inc.
Via
Business Wire
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
April 21, 2023
Via
Benzinga
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
April 20, 2023
Via
Benzinga
Cybin, Mind Medicine Among Top Psychedelic Movers Of Today
April 19, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 18, 2023
April 18, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 17, 2023
April 17, 2023
Via
Benzinga
Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More
April 17, 2023
Revolutionizing Psychedelics: 2 Industry Leaders Team Up On Clinical-Grade MDMA Capsules
Via
Benzinga
ATAI Life Sciences, Seelos Therapeutics Among Top Psychedelic Movers Of Today
April 14, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 13, 2023
April 13, 2023
Via
Benzinga
EXCLUSIVE: Investing In The Unique Growth Market Of Psychedelics
April 13, 2023
The global psychedelics market of drugs such as psilocybin, ketamine and LSD is booming and there are plenty of ways to get involved in the space.
Via
Benzinga
Cybin Offers Free Online Training To Facilitate Psychedelic Therapy
April 12, 2023
Cybin Inc. (NYSE: CYBN), a clinical-stage biopharma company developing innovative psychedelic-based treatment options, is launching a free online facilitation training course.
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 12, 2023
April 12, 2023
Via
Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Launches EMBARK OA, a Cost-Free Facilitator Training Program for Psychedelic Therapy
April 12, 2023
Via
Investor Brand Network
Cybin Announces EMBARK Open Access, the First Free Online Course Providing Facilitator Training for Psychedelic Therapy
April 12, 2023
From
Cybin Inc.
Via
Business Wire
Psychedelic Stock Gainers And Losers From April 11, 2023
April 11, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 10, 2023
April 10, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 7, 2023
April 07, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 6, 2023
April 06, 2023
Via
Benzinga
Compass Pathways, GH Research Among Top Psychedelic Movers Of Today
April 05, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 4, 2023
April 04, 2023
Via
Benzinga
"Multi-Bagger" Portfolio Down 13% In March; Still Up Almost 6% YTD
April 04, 2023
The
Via
Talk Markets
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
April 03, 2023
Via
Benzinga
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
38
39
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
